[1] WHO. Global tuberculosis report 2021[R]. Geneva:WHO Press,2022. https://www.who.int/tb/publications/global_report/en/.
[2] 刘志辉,钟球.全面应对耐多药结核病的挑战——问题、困惑、行动和希望[J].实用医学杂志,2022,38(13):1573-1577. DOI:10.3969/j.issn.1006-5725.2022.13.001.
[3] 刘剑君,王黎霞.现代结核病学[M]. 2版. 北京:人民卫生出版社,2022:404-440.
[4] Dookie N, Ngema SL, Perumal R, et al. The changing paradigm of drug-resistant tuberculosis treatment: successes, pitfalls, and future perspectives[J]. Clin Microbiol Rev, 2022, 35(4): e0018019. DOI: 10.1128/cmr.00180-19.
[5] Kohli M, MacLean E, Pai M, et al. Diagnostic accuracy of centralised assays for TB detection and detection of resistance to rifampicin and isoniazid: a systematic review and meta-analysis[J]. Eur Respir J, 2021, 57(2): 2000747. DOI:10.1183/13993003.00747-2020.
[6] Bertram G Katzung. 基础与临床药理学[M]. 金有豫, 唐玉, 张殿增, 译. 13版. 北京: 人民卫生出版社, 2020: 679-687.
[7] Vilchèze C, Jacobs WR. The mechanism of isoniazid killing: clarity through the scope of genetics[J]. Annu Rev Microbiol, 2007, 61: 35-50. DOI: 10.1146/annurev.micro.61.111606.122346.
[8] CRyPTIC Consortium and the 100,000 Genomes Project, Allix-Béguec C, Arandjelovic I,et al. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing[J]. N Engl J Med, 2018, 379(15): 1403-1415. DOI: 10.1056/NEJMoa1800474.
[9] Krittanan P, Srimanote P, Thawornwan U, et al. Spoligotype-based population structure and isoniazid-resistance gene mutation of Mycobacterium tuberculosis isolates from Thailand[J]. J Glob Antimicrob Resist, 2022, 30: 319-325. DOI: 10.1016/j.jgar.2022. 06.013.
[10] Narmandakh E, Tumenbayar O, Borolzoi T, et al. Genetic mutations associated with isoniazid resistance in mycobacterium tuberculosis in Mongolia[J]. Antimicrob Agents Chemother, 2020, 64(7): e00537-20. DOI: 10.1128/AAC.00537-20.
[11] Isakova J, Sovkhozova N, Vinnikov Denis, et al. Mutations of rpoB, katG, inhA and ahp genes in rifampicin and isoniazid-resistant Mycobacterium tuberculosis in Kyrgyz Republic[J]. BMC Microbiol, 2018, 18(1): 22. DOI: 10.1186/s12866-018-1168-x.
[12] Huo F, Lu Jie, Zong Z, et al. Change in prevalence and molecular characteristics of isoniazid-resistant tuberculosis over a 10-year period in China[J]. BMC Infect Dis, 2019, 19(1): 689. DOI: 10.1186/s12879-019-4333-4.
[13] Ghodousi A, Tagliani E, Karunaratne E, et al. Isoniazid resistance in Mycobacterium tuberculosis is a heterogeneous phenotype composed of overlapping MIC distributions with different underlying resistance mechanisms[J]. Antimicrob Agents Chemother, 2019, 63(7): e00092-19. DOI: 10.1128/AAC.00092-19.
|